Corcept Therapeutics CORT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $769.1M+12.2% | $761.41M+12.8% | $741.17M+17.9% | $716.08M+25.7% | $685.45M+30.9% | ||
| $13.46M+25.2% | $12.98M+19.3% | $13.39M+36.6% | $11.66M+35.9% | $10.75M+40.9% | ||
| $260.44M+4.5% | $254.91M+3.2% | $260.35M+12.6% | $250.84M+15.3% | $249.12M+23.3% | ||
| $503.42M+60.0% | $448.73M+60.1% | $401.86M+64.6% | $351.63M+63.1% | $314.71M+63.9% | ||
| $777.32M+35.3% | $716.61M+33.2% | $675.6M+39.2% | $614.13M+39.0% | $574.58M+43.1% | ||
| -$8.22M-107% | $44.8M-67.3% | $65.57M-54.3% | $101.95M-20.3% | $110.87M-9.1% | ||
| -1.1%-17.2pp | 5.9%-14.4pp | 8.8%-14.0pp | 14.2%-8.2pp | 16.2%-7.1pp | ||
| $20.35M-19.4% | $21.67M-11.7% | $22.94M-0.2% | $24.26M+11.1% | $25.25M+31.6% | ||
| $12.13M-91.1% | $66.46M-58.8% | $88.51M-46.8% | $126.21M-15.7% | $136.12M-3.5% | ||
| -$35.21M-1,759% | -$33.19M-264% | -$17.6M-172% | -$7.44M-131% | $2.12M-90.8% | ||
| $47.34M-64.7% | $99.65M-29.4% | $106.11M-25.2% | $133.66M+6.1% | $133.99M+13.5% | ||
| 6.2%-13.4pp | 13.1%-7.8pp | 14.3%-8.2pp | 18.7%-3.5pp | 19.5%-3.0pp | ||
| $0.35-69.6% | $0.82-33.3% | $0.87-31.0% | $1.12-0.9% | $1.15+8.5% | ||
| -$6.94M-106% | $45.95M-66.6% | $66.71M-53.7% | $103.12M-19.8% | $112.01M-8.9% | ||
| -0.9%-17.2pp | 6%-14.4pp | 9%-13.9pp | 14.4%-8.2pp | 16.3%-7.1pp | ||
| -$8.22M-107% | $44.8M-67.3% | $65.57M-54.3% | $101.95M-20.3% | $110.87M-9.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Corcept Therapeutics's revenue?
- Corcept Therapeutics (CORT) generated $769.1M in revenue over the trailing twelve months, up 12.2% year over year.
- Is Corcept Therapeutics profitable?
- Corcept Therapeutics reported $47.3M in net income over the trailing twelve months, a 6.2% net margin.
- What are Corcept Therapeutics's profit margins?
- Gross margin is 98.3% and operating margin is -1.1%, with a 6.2% net margin.
- What is Corcept Therapeutics's earnings per share?
- Corcept Therapeutics's diluted EPS over the trailing twelve months is $0.35.
- Where does Corcept Therapeutics's income statement data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
